Stents Move Up to the Carotid

Just as drug-eluting stents prevent heart attacks by maintaining the patency of coronary arteries, so do carotid artery stents prevent strokes by keeping carotid arteries open. Carotid artery stenting, like coronary stenting, is a minimally invasive, percutaneous procedure and both procedures use similar kinds of devices. The large cardiovascular device companies are all in clinical trials with carotid artery stents, but none is expected on the US market before 2005. Still, the market for carotids isn't likely to be nearly as big as that of coronary stents.

If drug-eluting stents are the Next Big Thing in interventional clinical practice, then carotid stents may be Another Big Thing. Even as their primary focus remains developing drug-eluting stents, the large cardiovascular device companies are progressing with clinical trials of carotid artery stents. The application of stents in the carotid artery may prove to be as effective in preventing strokes as coronary stents have been (and their progeny, drug-eluting stents, appear to be) at preventing heart attacks. For coronary stents, this is accomplished by maintaining the patency of coronary arteries. In the case of carotid artery stents, the key is to keep the carotid artery, the primary blood vessel leading to the brain, free of obstructions caused largely by atherosclerotic plaque build-up.

Carotid artery and coronary artery stenting share some things in common—they are minimally invasive, percutaneous procedures using similar kinds of...

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.